Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow

Doxorubicin is a risk factor for secondary lymphedema in cancer patients exposed to surgery or radiation. The risk is presumed to relate to its cytotoxicity. However, the present study provides initial evidence that doxorubicin directly inhibits lymph flow and this action appears distinct from its c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Pharmacol Exp Ther
Auteurs principaux: Stolarz, Amanda J., Sarimollaoglu, Mustafa, Marecki, John C., Fletcher, Terry W., Galanzha, Ekaterina I., Rhee, Sung W., Zharov, Vladimir P., Klimberg, V. Suzanne, Rusch, Nancy J.
Format: Artigo
Langue:Inglês
Publié: The American Society for Pharmacology and Experimental Therapeutics 2019
Sujets:
Cardiovascular
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815939/
https://ncbi.nlm.nih.gov/pubmed/31439806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.257592
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires